-
Visit the Toolkit for an extensive collection of a-fib anticoagulation resources for the physician, educator, and patient.
-
Participants at the Interstate Postgraduate Medical Association (IPMA) calculating CHADS2 scores.
-
DID YOU KNOW?
-
BREAKING NEWS:
Read the full
press release. -
PARTNER QUOTATION:
-
Risk Assessment
The incidence of atrial fibrillation in the aging population continues to increase in frequency and predisposes patients to an increased risk for stroke. Assessment of risk for stroke is a significant and independent risk factor for stroke.
Bleed Risk
An important element weighing the risk of bleeding on anticoagulation is to assess it along with the risk of morbidity and mortality from stroke. The HASBLED Scale describes patient characteristics that affect bleeding risk.
Medication Information
The selection of the appropriate medical therapy requires a sound knowledge about the characteristics of these medications which include warfarin and newer medications such as dabigatran etexilate, rivaroxaban, apixaban, and edoxaban.
Patient Compliance
Consistency in medication compliance, diet, and activities are critical elements in a comprehensive care plan. An effective plan of care minimizes stroke risk while not creating a significant risk of bleeding.
Patient Management for Medical Procedures
Appropriate adjustments to medical therapies, close monitoring of patient status (pre- and post-operatively) and a coordinated plan for comprehensive anticoagulation management are essential to optimum patient outcomes.
TEAM-A is an innovative educational collaboration among ten organizations committed to improving patient outcomes through clinician education:
Commercial support is provided through an independent medical education grant from the Bristol-Myers Squibb/Pfizer Pharmaceuticals Partnership.
